Hydrochloric Acid

Hydrochloric Acid

SCHEMBL693350

Cl.O=C(OCc1ccccc1)C1CCCN1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HTR2C known ✓ P28335 1/20 0.54
HTR2B known ✓ P41595 1/20 0.54
GLA known ✓ P06280 1/20 0.45
GAA known ✓ P10253 1/20 0.43
TSHR P16473 1/20 0.65
BACE1 P56817 1/20 0.47
CTSC P53634 1/20 0.47
ELANE P08246 1/20 0.46
FABP7 O15540 1/20 0.44
FABP5 Q01469 1/20 0.44
ALDH1A1 P00352 2/20 0.44
FKBP1A P62942 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL630516 1.00 TSHR (0.65) TSHRHTR2CHTR2BBACE1CTSC
Hydrochloric Acid SCHEMBL1000787 1.00 TSHR (0.65) TSHRHTR2CHTR2BBACE1CTSC
SCHEMBL4069956 0.98 TSHR (0.63) TSHRHTR2CHTR2BBACE1CTSC
SCHEMBL693351 0.98 TSHR (0.63) TSHRHTR2CHTR2BBACE1CTSC
SCHEMBL630517 0.98 TSHR (0.63) TSHRHTR2CHTR2BBACE1CTSC
Hydrochloric Acid SCHEMBL630941 0.96 TSHR (0.64) TSHRHTR2CHTR2BBACE1ALDH1A1
Hydrochloric Acid SCHEMBL630943 0.96 TSHR (0.64) TSHRHTR2CHTR2BBACE1ALDH1A1
SCHEMBL6727374 0.94 TSHR (0.61) TSHRHTR2CHTR2BBACE1GLA
SCHEMBL630942 0.94 TSHR (0.61) TSHRHTR2CHTR2BBACE1GLA
SCHEMBL28676037 0.93 TSHR (0.60) TSHRHTR2CHTR2BBACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107474107-B Process for the preparation of GLYX-13 and compounds useful for the preparation of GLYX-13 江苏恩华药业股份有限公司 2023-01-17 CN claimed
CN-107474107-A GLYX 13 preparation method and the compound for preparing GLYX 13 江苏恩华药业股份有限公司 2017-12-15 CN claimed
US-5177006-A Enzyme inhibitors E. R. SQUIBB & SONS, INC. (US) 1993-01-05 US claimed
JP-8253497-A None JP disclosed
JP-10109999-A None JP disclosed
CN-122011092-A Method for preparing Pal-GQPR by LPPS 富乐马鸿凯(大连)医药有限公司 2026-05-12 CN disclosed
CN-122011092-A Method for preparing Pal-GQPR by LPPS 富乐马鸿凯(大连)医药有限公司 2026-05-12 CN disclosed
EP-4505875-A1 METHOD FOR CONTROLLING PARASITIC PLANTS AJINOMOTO CO., INC. (JP) 2025-02-12 EP disclosed
US-20250031699-A1 Method for Controlling Parasitic Plants AJINOMOTO CO., INC. (JP) 2025-01-30 US disclosed
CN-119012914-A Method for controlling parasitic plants 味之素株式会社 2024-11-22 CN disclosed
US-20240124539-A1 CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME NEW YORK UNIVERSITY 2024-04-18 US disclosed
US-4808741-A Process for preparing carboxyalkyl dipeptides TORCAN CHEMICAL LTD. (CA) 1989-02-28 US disclosed
EP-0253190-A2 Partially retro-inverted tuftsin analogues, method for the preparation thereof and pharmaceutical compositions containing them ENIRICERCHE S.p.A. (IT) 1988-01-20 EP disclosed
EP-0237264-A2 Process for preparing phosphonyloxyacyl amino acids and derivates thereof E.R. Squibb & Sons, Inc. (US) 1987-09-16 EP disclosed
CN-86101268-A The preparation method of new peptidase inhibitors 1987-02-04 CN disclosed
EP-0080283-B1 N-CARBOXYALKYLPROLINE-CONTAINING TRIPEPTIDES SMITHKLINE BECKMAN CORPORATION (US) 1986-01-29 EP disclosed
US-4500713-A TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID DERIVATIVE AS ANTIHYPERTENSIVE AGENT USV PHARMACEUTICAL CORPORATION (US) 1985-02-19 US disclosed
US-4456594-A N-Carboxyalkylproline-containing tripeptides SMITHKLINE BECKMAN CORPORATION (US) 1984-06-26 US disclosed
EP-0104546-A2 Therapeutic dipeptides USV PHARMACEUTICAL CORPORATION (US) 1984-04-04 EP disclosed
EP-0080283-A1 N-carboxyalkylproline-containing tripeptides SMITHKLINE BECKMAN CORPORATION (US) 1983-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250031699-A1 Method for Controlling Parasitic Plants PTMS, DAO, GNMT HTR2C 2383/4885HTR2B 3958/4885GLA 2541/4885
US-20240124539-A1 CROSSLINKED HELIX DIMER MIMICS OF SOS AND METHODS OF USING SAME SOS2, SOS1, F2 HTR2C 2102/4885HTR2B 2923/4885GLA 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.